Tag: antibodies

University of Utah Health scientists are leading an effort to determine if salivary glands infected with the virus that causes COVID-19 could diminish a person’s long-term immunity to the disease after being immunized or after recovering from the illness. The investigation, supported by a two-year grant from the National Institutes of Health, will explore whether

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the current coronavirus disease 2019 (COVID-19). This modern plague shut down travel, business, education, and leisure activity for months as SARS-CoV-2 quickly spread to infect hundreds of millions around the world.        Achieving herd immunity has become a top priority and one which seemed

A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine. This really demonstrates that that we should combine broadly neutralizing antibodies with other immunostimulatory agents, especially those that may impact immune response. If we

Thought LeadersBin MaCo-Founder and PresidentRapid Novor, Inc In this interview, News-Medical speaks to Bin Ma, President of Rapid Novor, about their latest research that sequenced polyclonal antibodies using only proteomics. Please can you introduce yourself and tell us about your role at Rapid Novor. My name is Bin Ma. I am Rapid Novor’s co-founder and

In late December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and subsequently spread rapidly across the world. On the 11th of March 2020, the World Health Organization announced the global outbreak of coronavirus disease 2019 (COVID-19) as a pandemic. Scientists around the world are working extensively to develop new vaccines,

Antibodies aren't the only immune cells needed to fight off COVID-19 -; T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine. The researchers found that blood cancer patients with COVID-19 who

Seroprevalence studies have proved their worth in estimating the size and directionality of an outbreak of infectious disease, especially the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19). A new study posted to the medRxiv* preprint server describes the prevalence of SARS-CoV-2 antibodies in five representative regions of Germany.

Scientists have reported that in most cases, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, mildly infects infants. However, around 10% of infants experienced severe COVID-19 infection who required advanced medical treatments. In rare cases, even asymptomatic infection can result in Multisystem Inflammatory Syndrome in

Scientists have reported that in most cases, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, mildly infects infants. However, around 10% of infants experienced severe COVID-19 infection who required advanced medical treatments. In rare cases, even asymptomatic infection can result in Multisystem Inflammatory Syndrome in

Most people with cancer who are infected by the novel coronavirus produce antibodies at a rate comparable to the rest of the population–but their ability to do so depends on their type of cancer and the treatments they've received, according to a new study by researchers at Montefiore Health System and Albert Einstein College of

Six months after it was controversially hailed by Trump administration officials as a "breakthrough" therapy to fight the worst effects of Covid-19, convalescent plasma appears to be on the ropes. The treatment that infuses blood plasma from recovered Covid patients into people newly infected in hopes of boosting their immune response has not lived up

Florida newborn is the first baby in the US to be born with COVID-19 antibodies after mother received one dose of the vaccine while pregnant The unnamed woman, who is a frontline healthcare worker,  received one dose of Moderna’s coronavirus vaccine when she was 36 weeks pregnant Three weeks later, she gave birth to a healthy

COVID-19 antibodies were found in the blood of about one in five donations from unvaccinated donors in the first week of March, American Red Cross data show. The organization tested more than 3.3 million donations from unvaccinated people in 44 states between mid-June 2020 and early March 2021. Across the entire period, about 7.5 percent

SARS-CoV-2, the virus that causes COVID-19, has mutated throughout the pandemic. New variants of the virus have arisen throughout the world, including variants that might possess increased ability to spread or evade the immune system. Such variants have been identified in California, Denmark, the U.K., South Africa and Brazil/Japan. Understanding how well the COVID-19 vaccines

As new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, fueling the continued spread of the coronavirus disease 2019 (COVID-19) pandemic, a new study offers encouragement. Released as a preprint on the bioRxiv* server, the study reports the protection offered by antibodies elicited by natural infection against the newer variants

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were produced in response to vaccination or natural infection, or

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to wreak havoc across the globe. Scientists are racing to develop effective therapeutic regimens to combat the infection. One of therapy currently used to stimulate a robust immune response against the virus is monoclonal antibodies, a treatment used for

The coronavirus disease 2019 (COVID-19) pandemic – caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – is still causing hundreds of thousands of new cases globally. Therapeutic antibodies have been used to attempt to counter and contain the virus. Convalescent plasma (CP) obtained from recovered COVID-19 patients is also in use in many

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School of Medicine report that individual

Researchers at the California Institute of Technology in Pasadena have developed a software tool called "Variant Database" that has detected an emerging lineage of severe acute respiratory coronavirus 2 (SARS-CoV-2) isolates in New York. The novel SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to sweep the globe